Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Kathleen N. Moore; Amit M. Oza; Nicoletta Colombo; Ana Oaknin; Giovanni Scambia; Domenica Lorusso; Gottfried E. Konecny; Susana Banerjee; Conleth G. Murphy; János L. Tanyi; Hal W. Hirte; Jason Konner; Peter Lim; Monica Prasad-Hayes; Bradley J. Monk; Patricia Pautier; Jiao Wang; Anna Berkenblit; Ignace Vergote; Michael J. Birrer

doi:10.1016/j.annonc.2021.02.017

Abstract

This is the authors' abstract. We don't add key points for this paper.

In patients with platinum-resistant EOC, MIRV did not result in a significant improvement in PFS compared with chemotherapy. Secondary endpoints consistently favored MIRV, particularly in patients with high FRα expression. MIRV showed a differentiated and more manageable safety profile than chemotherapy.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Moore et al. (2021) studied this question.

synapsesocial.com/papers/69dacab64e9a02dbaa6848a1 https://doi.org/10.1016/j.annonc.2021.02.017

View Full Paper

Ask AI

Bookmark

Share

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Abstract

Ask about this paper

Discussion

Cite This Study

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading